Mylan Tops Earnings Estimates, Maintains Full-Year Forecast
- Allergy treatment EpiPen drives 33% jump in specialty sales
- Total revenue increases 8%, in line with analysts’ predictios
This article is for subscribers only.
Mylan NV posted second-quarter profit that beat analysts’ estimates as sales surged for its specialty drugs division, which includes the allergy treatment EpiPen.
Earnings excluding some items were $1.16 a share, the company said Tuesday in a statement, topping the $1.14 average of predictions compiled by Bloomberg. Revenue rose 8 percent to $2.56 billion, in line with estimates of $2.57 billion.